Zimmer Biomet/$ZBH
1D1W1MYTD1Y5YMAX
Capital at risk
About Zimmer Biomet
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
- Ticker
- $ZBH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 17,000
- Headquarters
- Warsaw, United States
- Website
- www.zimmerbiomet.com
Zimmer Biomet Metrics
BasicAdvanced
$18B
23.45
$4.12
0.47
$0.96
0.99%
Price and volume
Market cap
$18B
Beta
0.47
52-week high
$106.88
52-week low
$79.12
Average daily volume
2M
Dividend rate
$0.96
Financial strength
Current ratio
1.691
Quick ratio
0.741
Long term debt to equity
0.497
Total debt to equity
0.592
Dividend payout ratio (TTM)
23.35%
Interest coverage (TTM)
4.90%
Profitability
EBITDA (TTM)
2,520.9
Gross margin (TTM)
69.52%
Net profit margin (TTM)
9.48%
Operating margin (TTM)
16.60%
Effective tax rate (TTM)
13.56%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
3.88%
Return on equity (TTM)
6.41%
Valuation
Price to earnings (TTM)
23.453
Price to revenue (TTM)
2.219
Price to book
1.46
Price to tangible book (TTM)
-10.52
Price to free cash flow (TTM)
17.502
Free cash flow yield (TTM)
5.71%
Free cash flow per share (TTM)
5.516
Dividend yield (TTM)
0.99%
Forward dividend yield
0.99%
Growth
Revenue change (TTM)
8.62%
Earnings per share change (TTM)
0.17%
3-year revenue growth (CAGR)
5.75%
10-year revenue growth (CAGR)
1.22%
3-year earnings per share growth (CAGR)
19.72%
10-year earnings per share growth (CAGR)
14.15%
10-year dividend per share growth (CAGR)
0.43%
What the Analysts think about Zimmer Biomet
Analyst ratings (Buy, Hold, Sell) for Zimmer Biomet stock.
Analyst projections of the future price of Zimmer Biomet stock.
Bulls say / Bears say
Zimmer Biomet beat Wall Street’s Q2 2026 expectations and raised its full-year 2026 guidance for reported sales, organic revenue growth, adjusted EPS, and share repurchases, reflecting confidence in its strategic execution and market demand. (Reuters)
U.S. organic revenue growth of 4.6% in Q2 2026 outpaced the broader orthopedic market estimate of 4–5%, underscoring Zimmer Biomet’s strong competitive position in its core market. (Reuters)
Zimmer Biomet generated robust operating cash flow of $448 million and free cash flow of $308 million in Q2 2026, up 18% and 24% year-over-year respectively, supporting its ability to invest in innovation and return capital to shareholders. (Reuters)
Zimmer Biomet’s adjusted gross margin contracted by 120 basis points and its adjusted operating margin fell by 210 basis points year-over-year in Q2 2026, reflecting margin pressure from ongoing investments and pricing headwinds. (Reuters)
The departure of CFO Suketu Upadhyay in April 2026 and appointment of an interim CFO introduce near-term financial leadership uncertainty amid strategic execution and cost-management efforts. (Reuters)
Organic constant-currency revenue growth in Q2 2026 was just 4.0%, suggesting a potential deceleration in demand momentum following stronger growth rates in the prior year. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Zimmer Biomet Financial Performance
Revenues and expenses
Zimmer Biomet Earnings Performance
Company profitability
Upcoming events
Zimmer Biomet News
AllArticlesVideos
Funds containing Zimmer Biomet
AllEURGBPUSD
Fund name | Fund size | $ZBH weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 2.51% |
VanEck Morningstar Wide Moat£MOGB | £354M | 2.51% |
iShares Ageing Population€AGED | €822M | 0.50% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.31% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.